

☰ Menu



22-25 JANUARY 2018 // MIAMI



ENQUIRE HERE

SPONSORSHIP ENQUIRY

# Speakers

---

## Dr David Lebwohl

Senior Vice President & Global Program Head, CAR-T Program, **Novartis**

David Lebwohl, M.D. is Senior Vice President and Executive Global Program Head for the CART Team in the Novartis

antigen receptor T-cell therapies at Novartis.

He was formerly global head of Oncology Clinical Development, and Global Program Head for Afinitor, an oral mTOR inhibitor, within Novartis Oncology. He graduated from Harvard College magna cum laude in Biochemical Sciences and was then a Graduate Research Student in Tumour Immunology at University College London. He graduated as doctor of medicine from the Yale University School of Medicine.

Following post-graduate training at Brigham and Women's Hospital and Memorial Sloan-Kettering Cancer Center in internal medicine, hematology and medical oncology, he joined the staff of Memorial Sloan-Kettering on the Breast Cancer Service. More recently, Dr. Lebwohl has focused on the clinical development of new cancer drugs, first at Bristol Myers Squibb, where he lead the development of JM-216, an oral platinum, and ixabepilone, an epothilone, as well as other compounds. He joined Novartis Oncology in 2002 where he was responsible for the development of Afinitor (RAD001) from phase 1 through five NDA/MAA approvals. He also led the clinical development of PTK787, a VEGFR inhibitor, panobinostat, a deacetylase inhibitor, and PKC412, a FLT3 kinase inhibitor.

---

## Sessions

📅 17-Jan-2017 ⌚ 18:00 - 19:30

**Afternoon Super Session (Shared with Immunotherapy World 2017): Changing Modern Medicine**

📅 18-Jan-2017 ⌚ 12:10 - 12:40

**A compare and contrast of the latest clinical data from - and the processes and materials used by - the T cell immunotherapy sector's most advanced pharma and biotech companies**

## Featured Speakers

**Martin Andrews**

Senior Vice President, Global Rare Diseases , **GlaxoSmithKline**

**Xavier Anguela**

Discovery Research Lead , **Spark Therapeutics**

**Naomi Aronson**

Executive Director of Clinical Evaluation, Innovation and Policy in the Office of Clinical Affairs , **Blue Cross and Blue Shield Association**



Attending pharma/biotech companies include

---

abbvie







# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.